Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 270 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatic Failure Clear all

Conditions: Acute Liver Failure
Interventions: OCR-002; Drug
Lead sponsor: Ocera Therapeutics, Inc.; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Hepatic Encephalopathy
Interventions: PPI deprescribing; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Intestinal Failure-associated Liver Disease
Interventions: Not listed
Lead sponsor: Protara Therapeutics; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • Kissimmee, Florida • Chicago, Illinois + 7 more

Conditions: Hepatic Insufficiency, Healthy
Interventions: Olomorasib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Lake Forest, California • Miami, Florida • Orlando, Florida + 1 more

Conditions: Hepatic Insufficiency, Antibacterial Agents
Interventions: MK-3866; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Acute Alcoholic Hepatitis
Interventions: ELAD treatment, Standard of care (Control); Biological · Other
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more

Conditions: Acute Liver Failure
Interventions: N-acetylcysteine (NAC), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more

Conditions: Hepatic Insufficiency & Healthy Subjects
Interventions: Zanubrutinib; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)
Interventions: Shunt Closure; Procedure
Lead sponsor: Prof. Valérie Mc Lin; Other
Eligibility: 1 Day and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: New Haven, Connecticut • Chicago, Illinois

Conditions: Hepatic Encephalopathy, HE, Cirrhosis, Altered Mental Status, AMS
Interventions: Lactulose, Polyethylene Glycol 3350; Drug
Lead sponsor: New York Presbyterian Brooklyn Methodist Hospital; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Edgewater, Florida • Miami, Florida • Orlando, Florida + 2 more

Conditions: Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
Interventions: calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal; Drug · Procedure · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more

Conditions: Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
Interventions: miroliverELAP treatment; Combination Product
Lead sponsor: Miromatrix Medical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 5 more

Conditions: Liver Failure
Interventions: Vasopressin, Normal saline placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hepatic Insufficiency
Interventions: LY3841136; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Liver Insufficiency
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cirrhosis
Interventions: SYNB1020, Placebo; Drug · Other
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Coronado, California • Rialto, California • Charleston, South Carolina + 2 more

Conditions: End Stage Liver DIsease, Sarcopenia, Sarcopenic Obesity, Cirrhosis
Interventions: MAsS; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Hepatic Impairment
Interventions: Tozadenant; Drug
Lead sponsor: Biotie Therapies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
Interventions: Not listed
Lead sponsor: eMyosound SAS; Industry
Eligibility: 60 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Liver Failure
Interventions: Focus Groups, Personal Interviews; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 13 Years and older
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2020
U.S. locations: 4
States / cities: Philadelphia, Pennsylvania • Houston, Texas

Conditions: Hepatic Insufficiency
Interventions: Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 5
States / cities: Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more

Conditions: Cirrhosis, Hepatic Encephalopathy
Interventions: Neurofit (oculometric testing); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions: High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year to 18 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Search by objective public record fields.

Emergency Use of OCR-002 in Acute Liver Failure (ALF)

Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

International Registry of Congenital Portosystemic Shunt (IRCPSS)

Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)

A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

Metabolomics of Liver Regeneration Following Partial Hepatectomy in Healthy Living Liver Donors

Safety, Tolerability and Pharmacodynamics of SYNB1020

Adverse Outcomes and Mortality in Liver Transplant

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

US Benchmarking Clinical Study

Understanding Patient's Knowledge and Use of Acetaminophen

A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment

Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease

TReatment for ImmUne Mediated PathopHysiology